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steatohepatitis were divided into three groups depending on the increase in the body 
mass index and the presence of biliary tract pathology. The humoral immune system 
state was evaluated by the levels of immunoglobulins A, M and G and the content of 
circulating immune complexes.
Results. In patients with non-alcoholic hepatic steatosis and non-alcoholic 
steatohepatitis, concomitant obesity and biliary tract pathology, there were observed 
abnormalities in the humoral component of the immune system with possible 
increase in the levels of major immunoglobulin classes as well as in the content of 
circulating immune complexes being more pronounced in patients with non-alcoholic 
steatohepatitis compared to patients with non-alcoholic hepatic steatosis (p<0,05) 
and apparently healthy persons (p<0,001). The increase in the body mass index led 
to a significant increase in the levels of Ig A, M, G and the activation of circulating 
immune complexes.More significant changes in humoral indices were observed in 
patients with chronic non-calculous and calculous cholecystitis in the presence of 
inflammatory BT changes during the exacerbation of the pathology compared to 
patients who underwent cholecystectomy on the background of the aggravation of 
postcholecystectomy syndrome.
Conclusions. The obtained data indicated that one of the elements in the 
pathogenesis of non-alcoholic fatty liver disease with concomitant OB and BT 
pathology is a significant change in the indicators of humoral immunity, namely the 
increase in the levels of Ig (A, M, G) and circulating immune complexes which depend 
on the clinical form (non-alcoholic hepatic steatosis or non-alcoholic steatohepatitis), 
increase in the body mass index and the presence of BT comorbidity.
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Aortic valve stenosis (AS) is the most common form of valvular heart disease 
in the elderly population and frequently occurs in conjunction with coronary 
artery disease and chronic heart failure (CHF). Meldonium had shown myocardial 
cytoprotection effect, however the role of meldonium in the elderly pts with CHF and 
AS disease remains debatable. 
Objectives: we aimed to evaluate the effects of meldonium in elderly patients 
with CHF with preserved ejection fraction and AS. 
Methods: 51 pts (31 M, 20 F, mean age – 74,97±2,75 years) with CHF NYHA 
I–III class and AS were enrolled. 26 (51 %) pts received the standard treatment 
and meldonium 500 mg/day (1 group), while 25 (49 %) (2 group) – received only the 
standard treatment for 12 weeks. Echocardiographic parameters, 6 min walk test 
were performed in all pts at baseline and at the end of the study. Aortic valve area 
(AVA) was calculated by Doppler echocardiography in all pts. 
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Results. Echocardiographic parameters, 6 min walk test distance did not 
differ significantly between the groups (p=0,027). After 12 weeks of treatment 
with meldonium the incidence of exertion-related symptoms, including chest pain, 
dyspnoea, fatigue were significantly lower in the 1st  in comparison with the 2nd 
groups (p=0,05). The distance of the 6 min walk test in 31 % pts have been increased 
in the 1st group by 26,47 % (р<0.01); in the 2nd group in 20 % pts – by 9,47 % 
(р<0,01). 6 min walk test correlated to NYHA functional class (r=0,25; р<0,05). 
After 12 weeks of treatment with meldonium the 1st group had significantly less 
stenotic progression, than the 2nd group (average decrease in AVA; 0,14 sm2 versus 
0.19 sm2, respectively (p<0,05)).  
Conclusion. Meldonium is effective and safe for the elderly pts with CHF and 
preserved ejection fraction and AS. Meldonium reduces progression of CHF and AS. 
Its administration may provide benefits for the reduction of hospitalizations and 
mortality in this category patients.
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Background. According to ESC guidelines 2016 for the diagnosis and treatment 
of heart failure, a patient who has never exhibited the typical symptoms and/or signs 
of heart failure (HF) and with a reduced left ventrical (LV) ejection fraction (EF) is 
described as having asymptomatic LV systolic dysfunction (ALVD). The absence of 
clinical signs and symptoms of HF may reflect the delay in the process of diagnosis 
and therapy.
IHD is the most common comorbidity and the leading cause of hospitalization 
in patients with COPD. Indeed, numerous epidemiological studies have shown 
that COPD, independent of cigarette smoking and aging, doubles the risk of CVD 
hospitalization and death. To date, the mutual burdens of IHD and COPD have been 
proven. Left ventricular dysfunction in IHD aggravates the effects of COPD through 
impairment of pulmonary hemodynamics. The basis for unfavorable interaction of 
IHD and COPD is systolic and diastolic dysfunction of the left ventricle due to its 
hypertrophy, increased aortic stiffness, hypoxia effect, right ventrical dysfunction.
The aim of this study was to estimate of asymptomatic LVD in patients with 
IHD and COPD while in a stable condition.
Materials and methods: 45 patients were included in this study (male – 32 
(71,1 %), female – 13 (28,9 %)). All patients had IHD combined with COPD, and had 
never exhibited the typical symptoms and/or signs of HF. Mean age was 60,0±10,01 
years. Patients were divided into groups according to GOLD 2017. In the control group 
were included 20 patients with IHD without COPD, relevant by age, sex and severity, 
